Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives (Epidemiology & pathogenesis)
- What is GCA?
- Epidemiology
- Incidence varies by geography
- Pathogenesis
- Vessel targets in GCA
- Vessel pathology
- At the tissue level
- Etiology (1)
- Genome wide association study in GCA
- Etiology (2)
- The epidemiology of giant cell arteritis
- Infections in GCA
- Loss of normal inhibition
- PD-1 immune checkpoint in giant cell arteritis
- Objectives (symptoms, signs & diagnostic testing)
- Symptoms of GCA
- Cranial symptoms (1)
- Cranial symptoms (2)
- Visual symptoms
- Musculoskeletal symptoms
- Large vessel manifestations
- Investigations
- Labs in GCA
- Temporal artery biopsy (1)
- Temporal artery biopsy (2)
- Imaging
- CT or MR angiography
- Positron emission tomography (PET)
- Temporal artery U/S
- Objectives (Approach to treatment)
- Glucocorticoids
- Relapses are common
- Difficulty discontinuing treatment
- Steroid side effects are common
- Steroid-sparing options (Tocilizumab)
- Roles of IL-6 in GCA
- Tocilizumab (TCZ): IL-6 inhibitor
- Results of GiACTA
- Tocilizumab summary
- Steroid-sparing options (Methotrexate)
- Methotrexate trials
- Methotrexate meta-analysis
- Methotrexate summary
- Steroid-sparing options (Abatacept)
- A role for T cell inhibition
- Abatacept
- Abatacept trial
- Steroid-sparing options (Other options)
- Other targets
- Ustekinumab studies
- Other drugs
- Adjunctive therapies (1)
- Adjunctive therapies (2)
- Objectives (prognosis)
- Prognosis & outcome (Mortality)
- Overall survival in GCA
- Mortality in subgroups
- Prognosis & outcome (End organ damage)
- Vision loss
- Visual loss
- Stroke in GCA (1)
- Stroke in GCA (2)
- Aortic aneurysm & dissection
- A later complication
- Need for systematic screening
- Aortic disease
- How to screen for aortic disease
- Objectives (Conclusion)
Topics Covered
- Pathogenesis of GCA
- Common presenting features
- Role of biopsy and diagnostic imaging studies
- Review of available therapies, including steroid-sparing options
- Survival and risk of end-organ damage
Talk Citation
Clifford, A. (2024, October 22). An approach to giant cell arteritis (GCA) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GVJI5361.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Alison Clifford has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dr. Alison Clifford.
I'm an Assistant Professor of Rheumatology at
the University of Alberta in Edmonton, Canada.
And today we will review "An Approach to the Diagnosis and
Treatment of Giant Cell Arteristis or GCA".
0:16
The objectives for today's lecture are number
one to review the epidemiology and current understanding of disease pathogenesis in GCA.
Number two to discuss the common symptoms and signs that should lead one to
consider this diagnosis as well as the appropriate workup to be undertaken.
And number three to review the approach to
treatment and latest data on disease prognosis.
Beginning first with epidemiology,
0:41
Giant cell arteristis is a primary systemic large vessel
vasculitis characterized by granulomatous inflammation at the blood vessel walls.
Classically, it targets the temporal arteries,
thoracic aorta and major branch vessels.
However, it bears keeping in mind that any medium to large vessel may be affected.
1:01
By definition, giant cell arteristis is a disease affecting persons over
the age of 50 and it is about three times more common in women than men.
The incidence of disease appears to increase
steadily with increasing age with peak onset in
the eighth decade of life and a mean age at diagnosis of 76.6 years.
1:20
The incidence of GCA appears to vary significantly based on geography and ethnicity.
It is most common in patients of Northern European or Scandinavian descent.
Less common in those living in
Mediterranean countries and less common still in patients from Australia and Japan.
Accordingly, incidence rates based on
clinical diagnosis or positive temporal artery biopsy vary from as low
as 3.2 in Australia to 18.8 in Sweden per 100,000 persons greater than the age of 50.
With prevalence rates of 1.5 in Japan
to 204 in Olmsted County Minnesota per 100,000 person.
Although epidemiologic data supports these numbers,
this may in fact, be an underestimate of disease burden.
In one sequential histopathologic review of
temporal arteries taken from consecutive autopsies in Sweden,
the true prevalence of histopathologic temporal arteritis
is appeared to be closer to one percent.